Cannabis based drug for COVID-19 developed by Jamaican Scientist awaiting approval

Dr Henry Lowe

(JAMAICA GLEANER) — Jamaican researcher Dr Henry Lowe is anticipating endorsement of a patent for a cannabis-based medication that could be a triumphant solution for the novel coronavirus, The Gleaner has learnt.

A source said that Lowe would need to hang tight in line for half a month prior to knowing whether the medication demonstrates helpful against COVID-19.

group of coronaviruses.
The epic coronavirus, likewise called SARS-CoV-2, has separated itself from its family by its infectiousness and demise rate.

COVID-19 originally rose in Wuhan, China, in December 2019, and has later snowballed into a worldwide pandemic guaranteeing right around 70,000 lives from more than 1.2 million contaminations.

Lowe is an eminent Jamaican researcher who is broadly perceived for his broad research in the utilization of weed to treat malignant growth and different infections.

Through his organization, Bio-Tech Research and Development Institute Limited, Lowe has gotten endorsement from the United States Patent Office for a cannabis-based medication utilized for treating glaucoma and nearsightedness, or partial blindness.

Jamaica's decriminalization of ganja has opened up the market for Lowe and different speculators intrigued by the restorative weed advertise.

Agribusiness Minister Audley Shaw accepts that the rising clinical ganja industry will get one of Jamaica's quickest developing parts and could be worth as much as J$16 billion by 2022.

The worldwide business has been evaluated at US$500 billion.

Lowe has been working out his interests as of late, with Canadian firm Atlas Biotechnologies Inc infusing US$5.75 million for a stake in Flavocure, a US-enlisted organization claimed by Lowe. The Jamaican's outfit was esteemed in 2018 at US$29 million.

Flavocure is one organization inside the Eden Gardens Group of Companies held by Lowe.